Projektbeschreibung
Antimikrobielle Resistenz von innen bekämpfen
Die Fähigkeit von Krankheitserregern, gegen Antibiotika Resistenz zu entwickeln, bekannt als antimikrobielle Resistenz (AMR), verursacht jedes Jahr Millionen Todesfälle und stellt weltweit eine große Gesundheitsbedrohung dar. Bakterien, die gegen mehrere oder alle verfügbaren Arzneimittel resistent sind, stellen ein Alptraumszenario dar, das zur nächsten globalen Pandemie führen könnte. Ziel des vom Programm HORIZONT finanzierten Projekts IN-ARMOR ist es, die körpereigenen Abwehrmechanismen zur Bekämpfung von antimikrobieller Resistenz zu stärken. Die Forschenden werden computergestütztes Arzneimitteldesign einsetzen, um eine neue Klasse von Immunsystemaktivatoren zu entwickeln, die über ein nanotechnologisches Verabreichungssystem verabreicht werden. Diese Aktivatoren werden in präklinischen Modellen auf ihre Wirksamkeit geprüft. Das Projektteam zielt darauf ab, die mit der Entwicklung von Antibiotika verbundenen Engpässe zu überwinden und eine alternative Behandlung für antimikrobielle Resistenz anzubieten.
Ziel
Antimicrobial resistance (AMR) & multi-drug resistance, whereby pathogens evolve to resist antibiotic drugs, is designated by WHO one of the top 10 health threats of our time and is a top 3 priority health threat requiring EU level coordination. AMR was estimated to be linked to 4.95 million deaths in 2019. The next global pandemic could be a multi-drug resistant bacterium, or emergence of ‘pan-drug’ resistant strains (resistant to all existing drugs). Alternative therapeutic approaches are proving to be expensive and slow to develop, whilst also facing the risk of evolving strains. The innate immunity presents the strongest potential to tackle AMR as it can generate antimicrobial molecules and proteins that directly inhibit microbial survival. Inducing such proteins has shown effective antimicrobial activity against bacteria, viruses, fungi & protozoa.
Building on this approach, leading professors and researchers from 9 Universities and research institutes are collaborating with 7 medical and industry partners representing 9 EU countries to introduce a novel class of immune system inducers able to enhance the body’s own innate microbial defence mechanisms to combat AMR and reduce incidence of the 13 listed most dangerous infections (including 2 of the top 3 priority-1 infections).
IN-ARMOR will optimise an already developed drug platform using Computer Aided Drug Design, and in-silico approaches, in tandem with a nanotech-based drug delivery system for the first target indication. The developed therapy will be pre-clinically validated for safety and efficacy in-vitro and in vivo to complete all investigational Medicinal Product requirements.
Upon completion, IN-ARMOR will be prepared for clinical validation. Upon commercialisation, IN-AMOR could potentially save more 4Mn lives worldwide and result in the significant burden reduction of antibiotic development with long-term cost reduction impact of €107Bn, whilst reducing the global disease burden by 96.84Mn DAL
Wissenschaftliches Gebiet
- natural sciencesbiological sciencesmicrobiologybacteriology
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Schlüsselbegriffe
Programm/Programme
Aufforderung zur Vorschlagseinreichung
HORIZON-HLTH-2022-DISEASE-06-two-stage
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
HORIZON-RIA - HORIZON Research and Innovation ActionsKoordinator
101 Reykjavik
Island